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n June 2010, a small trial demonstrated for the first time that imaging metastatic HER-2 -positive breast cancer lesions is possible in patients only a few hours after injecting a radiolabeled peptide, which its developers call an Affibody. In all three patients in the study, the Affibody ABY-002 demonstrated good tumor penetrance, rapid blood clearance, and highbinding affinity to the HER-2 receptor, according to principal investigator Vladimir Tolmachev, Ph.D., from Sweden's Uppsala University.
With colleagues from the Royal Institute of Technology and the biotech company Affi body in Stockholm, Tolmachev obtained gamma-camera, SPECT (single-photon emission computed tomography), and PET -CT (positron emission tomography -computed tomography) images of the Affi body-bound receptor. The researchers then compared these images with results obtained using standard fl uorodeoxyglucose (FDG) -PET imaging. The Affi body illuminated nine of 11 metastases that had shown up with FDG -PET and did so as early as 2 hours after injection.
The study, published online in May in the Journal of Nuclear Medicine , is one of a growing number of investigations of new imaging agents designed to visualize detailed tumor-specifi c characteristics. "We need a new breed of physicians with training in nuclear medicine, diagnostic radiology, radiochemistry, and molecular biology, which today is in nobody's curriculum," said Hricak, who is radiology chief at Memorial Sloan -Kettering Cancer Center in New York. The requirements of the new subspecialty would include proficiency with the new imaging agents.
Response to Targeted Drugs
The new agents could supplement FDG -PET, the current "gold standard," which measures increased glucose metabolism. FDG -PET represents a step beyond conventional anatomic imaging and is widely used to detect cancers characterized by increased glucose metabolism, but it has shortcomings: It has limited sensitivity in early-stage disease detection in some tumors and cannot distinguish between cancer and infl ammation; it is not strictly tumor specifi c; and it cannot detect tumors that do not have increased glucose metabolism, such as prostate and some hepatocellular carcinomas.
The newer imaging agents are being tested in particular to monitor molecular changes in tumors during treatment with targeted drugs. The traditional gauge of response to a drug, tumor shrinkage, works well with chemotherapy drugs that are generally cytotoxic, i.e., they shrink tumors by killing cells. But targeted drugs, which interfere with specifi c molecules in or around tumor cells, are often cytostatic rather than cytotoxic -they arrest growth but may not shrink tumors. "Metabolic changes of tumors treated with targeted therapies do not necessarily occur at the same speed or magnitude as those treated with cytotoxic therapy," said Steven Larson, Ph.D., chief of nuclear medicine at Memorial Sloan -Kettering. The molecular imaging of tumors, say Larson and other experts, could rapidly identify areas of cell death and other markers that show that drugs are hitting their target even without tumor shrinkage.
Another advantage of these imaging agents is that they offer the possibility of being coupled with treatments. Researchers at the National Cancer Institute, for instance, are developing a drug that will hone in on and kill HER-2 -positive tumors by using a toxin attached to HER-2 -targeting Affibodies ( Journal of Immunotherapy 2009; 32:817 -25) . "Ultimately, advances in HER-2 imaging represent a step toward a new 'image and treat ' strategy in patients with cancer," said Kirsten Bouchelouche, M.D., Ph.D., director of the University of Copenhagen's PET and cyclotron facility.
The next agent expected to receive regulatory approval is F-FLT (3 ′ -deoxy-3 ′ -[ 18 F] fl uorothymidine), a marker of thymidine kinase activity, which provides a measure of cell proliferation. In vitro tests suggest that FLT is a better marker than FDG for cytostatic drugs, Larson said. Pilot clinical studies show that reduction in FLT uptake levels after treatment is associated with good therapeutic response in lung and breast cancer, glioma, and lymphoma ( Quarterly Journal of Nuclear Medical Molecular Imaging 2009; 53:158 -66) . FLT has also demonstrated early response to lymphoma treatment ( Clinical Cancer Research 2007; 13:3552 -8) . "From our own research, we expect that FLT will be important for monitoring treatment response for gastric cancer and lymphoma treated with chemotherapy or radiation, and that it will be 
Decades of Research
Research in molecular imaging has been going on for decades but really began taking off about 10 years ago when PET -CT machines became standard in clinical settings, according to Larson. PET -CT scans use two complementary technologies to image tumors. PET identifi es molecular and functional changes, whereas CT scans image anatomic characteristics.
The NCI began funding a dedicated molecular imaging initiative in 2000 and started its own intramural program in 2009. Institute researchers are now conducting pilot trials with new agents to image apoptosis, amino acid transport, and fatty acid metabolism, said Peter Choyke, M.D., chief of NCI's molecular imaging program.
Most new tracers under development are for PET -CT scans because of the scans ' ubiquity and accuracy, although agents are also being developed for magnetic resonance imaging, sonograms, SPECT, and optical imaging ( see sidebar). PET imaging is more expensive but also more sensitive than magnetic resonance and SPECT for detecting injected imaging agents.
The molecular imaging agents for PET -CT fall into three categories, each with pros and cons. Monoclonal antibodies account for almost all, and are relatively easy to design, but they clear the body slowly because they are relatively large unless modifi ed. An alternative are peptides, such as Affi bodies, and engineered antibody fragments, which are smaller and often have favorable pharmacokinetics for imaging. Finally, labeled small molecules are being designed for imaging metabolite pathways and intracellular targets such as kinases, polymerases, and other proteins associated with cancer and other diseases. These agents are potentially the most useful, according to some: "The holy grail of molecular imaging is to develop agents capable of imaging intracellular pathways," said Weissleder, who is working to develop such agents.
Receptor-Based Imaging
In addition to Affi bodies, scientists are also radiolabeling trastuzumab (Herceptin), a monoclonal antibody that targets HER2, for imaging the receptor. Elisabeth de Vries, M.D., Ph.D., professor of medical oncology at the University Hospital in Groningen, The Netherlands, found that 45% of single tumor lesions seen with conventional imaging were visible using the radio labeled antibody, a gamma camera, and SPECT. De Vries also found new lesions in 13 of the 15 patients tested in this early study.
Because PET is more accurate and gives better quantitative information than SPECT, the team later developed an 89Zr -trastuzumab PET probe that shows good uptake, detection, and quantifi cation of HER-2 -positive metastases. Early clinical data in patients with metastatic breast cancer show excellent uptake and successful detection and quantifi cation in HER-2 -positive metastases, De Vries said. Her team is now testing that probe against standard imaging, also in patients with metastatic disease. PSMA is a well-characterized biomarker expressed at much lower levels than prostatespecifi c antigen on normal and abnormal but not cancerous prostate tissue. Larson's team reported results in the August 2010 Journal of Nuclear Medicine with a radiolabeled humanized antibody to PSMA, Zr-DFO-J591, demonstrating highly specifi c uptake in prostate tumor grafts and bone metastases in mice. Clinical trials are expected to begin with this PSMA-targeting PET -labeled diagnostic antibody early next year.
Other tracers for apoptosis, angiogenesis, lipogenesis, hypoxia, amino acid transport, and fatty acid metabolism are being developed by Sam Gambhir, M.D., Ph.D., professor of radiology and bioengineering at Stanford University. Gambhir is also developing a "super-FDG" that will distinguish between cancer and infl ammation and may be usable in pancreatic and ovarian cancers that do not display high glycolysis. He is particularly interested in angiogenesis and is developing several agents based on the family of integrins and other biomarkers of new blood vessel growth; he expects to start trials for one in February 2011. He is also working on non -PET-CT agents for angiogenesis, including microbubbles for use with SPECT. In an earlier stage of development are photoacoustic agents, which use light and sound waves.
In the near term, researchers are fi nding new uses for FDG. Now widely used for presurgical staging of some tumors, FDG could prove helpful in planning treatment and assessing response, according to researchers interviewed for this article. In September, several studies published in the Journal of Nuclear Medicine illustrated new uses for FDG. In one, imaging predicted event-free survival in patients with advanced Hodgkin lymphoma after two cycles of chemotherapy, and in another, FDG predicted early response in non -small-cell lung cancer patients taking erlotinib (Tarceva).
"FDG has great potential to predict tumor response to anticancer drugs," Mankoff said. "This is a big area for future development." 
Dr. Tolmachev has reported that he was

